Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zyprexa · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Olanzapine Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | Zyprexa® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Olanzapine Tablets 5 mg | DRUG | 5mg, single dose fed |
| Zyprexa® Tablets 5 mg | DRUG | 5mg, single dose fed |
Inclusion Criteria: 1\. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration....
Zyprexa is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials evaluating its pharmacokinetics. The drug is being developed by Viatris Inc. (NASDAQ: VTRS).
The molecular target of Zyprexa has not been disclosed. The drug is a small molecule in Phase 1 development for healthy volunteers, with studies focused on food and fasting effects on its absorption. No specific biological target has been publicly identified.
Zyprexa is being developed by Viatris Inc., a global healthcare company traded on NASDAQ under the ticker VTRS. The company is conducting Phase 1 clinical trials to evaluate the drug's pharmacokinetics in healthy subjects.
Zyprexa is in Phase 1 clinical development. Two Phase 1 studies have been completed, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities for any indication.
Zyprexa has two completed Phase 1 trials: NCT00647777, a food study of olanzapine tablets 5 mg and Zyprexa tablets 5 mg with 32 participants, and NCT00648921, a fasting study with 30 participants. Both were conducted in the United States with healthy adults aged 18 and older.
Zyprexa is being studied as a branded reference product in trials comparing it to generic olanzapine tablets. The trials NCT00647777 and NCT00648921 evaluate the bioequivalence of olanzapine 5 mg tablets versus Zyprexa 5 mg tablets under fed and fasting conditions.